Rethinking future development of molecular therapies in hepatocellular carcinoma: a bottom-up approach

Area of Science:

• Oncology
• Clinical Trial Design
• Molecular Therapeutics

Background:

• High failure rates in Phase 3 oncology trials necessitate strategic reevaluation.
• Systemic therapies increasingly rely on molecular-based patient selection.
• Hepatocellular carcinoma (HCC) molecular trials show poor success, with 4/5 Phase 3 trials failing in 5 years.

Purpose of the Study:

• To address the need for improved drug development strategies in oncology.
• To highlight the inadequacy of current molecular therapies in HCC clinical trials.
• To emphasize the necessity of refining selection criteria using molecular readouts for HCC trials.

Main Methods:

• Review of recent Phase 3 molecular therapy trials in hepatocellular carcinoma.
• Analysis of patient selection strategies in negative HCC trials.
• Identification of the need for biomarker-driven patient enrichment.

Main Results:

• Four out of five Phase 3 molecular therapy trials in HCC have failed.
• None of the failed HCC trials utilized enriched populations based on response biomarkers.
• A significant gap exists in utilizing molecular readouts for patient selection.

Conclusions:

• Current molecular therapy approaches in HCC are insufficient without optimized patient selection.
• Biomarker-driven enrichment strategies are essential for improving HCC clinical trial outcomes.
• Rethinking trial design and incorporating molecular insights are critical for advancing HCC treatment.